GRAIL

Cancer survivors often face a higher risk of new cancers due to the impact of prior cancer treatments, in addition to several other factors. On #TheCancerSignal, Dr. Eric Klein shares insights from the PATHFINDER study and other GRAIL data from 2024, revealing how multi-cancer early detection (MCED) testing can help survivors screen for recurrence and new cancers earlier. Hear about these important findings on proactive cancer screening. Apple Podcasts: https://apple.co/49vtDBR Spotify: https://spoti.fi/4io6YLz Transcripts and more: https://bit.ly/3Lx4g6t

Reflecting on the potential impact of multi-cancer early detection (MCED) testing, Dr. Daniel Mackey says, “If we can diagnose our patients at an earlier stage, not only does it improve their quality of life, and improve the morbidity associated with the treatments, but we can also reduce health care costs.” Hear from Dr. Mackey and Dr. Tyler Kang with Adventis Health about their experiences using MCED testing for cancer screening in this video.

Dak Prescott is on a mission to help people detect cancer early and through his foundation - Faith Fight, Finish - he is doing just that. Thank you Tad Carper of the Dallas Cowboys for sharing this impactful story of multi-cancer early detection. Rx only. See Important Safety Information: https://lnkd.in/d_fp9JR5 The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

In 2024, health systems across the U.S. continued to make significant strides toward expanding early cancer detection screening. In fact, more than 11,000 health care providers have ordered the Galleri test to date. Hear from leading physicians on how the adoption of multi-cancer early detection (MCED) screening is helping address an urgent unmet need. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests. Rx only. See Important Safety Information: http://bit.ly/33m8pFa #MCED #EarlyDetection #CancerScreening

We’re wrapping up 2024 with a research update with Dr. Eric Klein, Distinguished Scientist at GRAIL. In this episode of #TheCancerSignal, Dr. Klein shares GRAIL’s highlights from ASCO, ESMO, AACR and more - findings on repeat multi-cancer early detection (MCED) testing, MCED use in cancer survivors, economic impacts of cancer screening, and even a couple case studies. Don’t miss this episode! Apple Podcasts: https://apple.co/49vtDBR Spotify: https://spoti.fi/4io6YLz Transcripts and more: https://bit.ly/3Lx4g6t

After taking a multi-cancer early detection (MCED) test, Mercy informed Mike that the results showed a Cancer Signal Detected. Mercy quickly assembled a care team for Mike, who helped determine the necessary next steps. In this video, Mike talks with oncologist Dr. Daniel Mackey about his care team’s impact during his cancer experience: https://lnkd.in/d9qXVENh

We’re all wishing the Dallas Cowboys' Tad Carper a speedy recovery after learning about his recent cancer diagnosis. We are glad that Tad’s cancer was caught early, using the Galleri® multi-cancer early detection test as a first step. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. Rx only. See Important Safety Information: https://lnkd.in/d_fp9JR5

Rich believed he had low cancer risk based on his family health history. But after a recommendation from their doctor, Rich and his wife Staci decided to add multi-cancer early detection testing to their cancer screening routine. Learn more about his cancer experience.

According to the CDC, cancer is one of the leading causes of death for firefighters in the US. With the increased risks of modern fire environments, proactive cancer screening is critical. Watch to learn why these firefighter leaders are prioritizing multi-cancer early detection (MCED) testing as part of their annual health protocol for both active duty and retired service members. #FirefighterCancer #OccupationalCancer

We’ve reached a milestone in collaboration with AstraZeneca: the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. Learn more: https://bit.ly/3YSag0N #LungCancer